Letters to the Editor
Fosfomycin and breastfeeding
- Tamara Lebedevs
- Aust Prescr 2020;43:113
- 3 August 2020
- DOI: 10.18773/austprescr.2020.042
A recent article on the treatment of resistant urinary tract infections stated that small amounts of fosfomycin are excreted in breast milk so it is not recommended in breastfeeding.1 Fosfomycin absorption is largely dependent on the salt form – trometamol salts are modestly absorbed (34–58%) and calcium salts are poorly absorbed (<12%). Fosfomycin secreted into human milk would likely be in the calcium form and is unlikely to be absorbed.
Foods and the acidic milieu of the stomach both significantly reduce oral absorption. Concentrations secreted into human milk have been reported to be about 10% of what is present in maternal plasma.2-6 It is not likely that the amount present in breast milk would produce untoward effects in a breastfeeding infant. On balance fosfomycin may be used with caution.
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by any responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Pharmacist, Women and Newborn Health Service, King Edward Memorial Hospital, Perth